Permeon™ Biologics Announces the Appointment of Katherine S. Bowdish, Ph.D., as President and Chief Scientific Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Permeon™ Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the appointment of Katherine S. Bowdish, Ph.D., as president and chief scientific officer. Dr. Bowdish also joins the Permeon board of directors. Previously, Dr. Bowdish was the co-founder, president and chief executive officer of Anaphore, a platform-based drug development company pioneering Atrimers™, a new class of trivalent protein ph

Feed Date: 
February 23, 2012